Pharma BD Deal Intelligence
The Auryxia commercial engine worked; the vadadustat pipeline bet that justified the deal nearly sank the company
Full analysis, sources & comparables →Akebia and Keryx shares fell 18% and 12% respectively on the merger announcement; investors questioned dilution and the strategic logic of pairing a…
Vadadustat (Vafseo) won FDA approval for dialysis-dependent CKD anemia two years after the 2022 CRL, vindicating elements of the original merger thesis though…
Akebia FY2025 results: total net product revenue $227.3M (+49% YoY). Vafseo (vadadustat) $45.8M in its first full launch year (U.S. shipments began Jan…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Akebia and Keryx announced an all-stock merger in June 2018 to create a fully integrated kidney disease company with combined market cap ~$1.3B. Keryx shareholders held 50.6% of combined entity vs 49.4% Akebia. Combines Akebia's late-stage HIF-PH inhibitor vadadustat (anemia in CKD) with Keryx's commercial ferric citrate Auryxia (phosphate binder/iron replacement). Closed December 12, 2018 with $250M targeted cost synergies. UPDATE (post-2024): Vadadustat (Vafseo) launched in the U.S. dialysis market in Q1 2025; in FY2025 Akebia reported total net product revenue of $227.3M (+49% YoY), with Vafseo at $45.8M (first launch year) and the legacy Keryx asset Auryxia at $181.5M (https://www.globenewswire.com/news-release/2026/02/26/3245436/37519/en/Akebia-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Commercial-and-Pipeline-Highlights.html). Both 2018-merger renal assets are now commercial in a single company, substantially realizing the 'integrated kidney disease company' thesis — though far later and smaller than the 2018 Raymond James $606M vadadustat peak projection. In Oct 2025 Akebia abandoned the VALOR Phase 3 after an FDA Type C meeting and will not pursue a broad non-dialysis Vafseo label, bounding the asset to the dialysis segment (https://www.globenewswire.com/news-release/2025/10/28/3175989/37519/en/Akebia-Therapeutics-Provides-Update-on-Vafseo-for-Non-Dialysis-Patients.html).
The Auryxia commercial engine worked; the vadadustat pipeline bet that justified the deal nearly sank the company
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Akebia Therapeutics, Inc. / Keryx Biopharmaceuticals, Inc. (this deal) | 2018 | $1.3B | 42 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2018 deals · Hematology deals